Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development

CAMBRIDGE, Mass. ~ Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, has announced an expanded collaboration with Bristol Myers Squibb (NYSE: BMY) to develop Foundation Medicine's tissue-based test, FoundationOne®CDx as a companion diagnostic for Bristol Myers Squibb's investigational tyrosine kinase inhibitor, repotrectinib.

Repotrectinib is an orally administered TKI (tyrosine kinase inhibitor) being evaluated in an ongoing registrational Phase 1/2 trial called TRIDENT-1 for patients with TKI-naive or TKI-pretreated ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors. If the companion diagnostic is approved for these indications, and separately, the therapy is approved, oncologists would be able to use FoundationOne CDx to help identify appropriate patients for treatment with repotrectinib.

More on Boston Chron
Foundation Medicine's portfolio of FDA-approved comprehensive genomic profiling tests offer physicians blood and tissue-based testing options for detecting genomic alterations that help guide personalized treatment decisions. Currently, Foundation Medicine is the leader in companion diagnostic approvals with approximately 60% of all companion diagnostic approvals for NGS testing in the U.S.

Jason Adams, Vice President of Biopharma Enterprise Partnerships at Foundation Medicine said "We're proud to broaden our collaboration with Bristol Myers Squibb as they work to bring this exciting investigational therapy to patients living with ROS1 positive non-small cell lung cancer and NTRK positive solid tumors. This new collaboration builds on our ongoing research-driven partnership and furthers our shared commitment to deliver more treatment options to patients who need them."

The expanded collaboration between Foundation Medicine and Bristol Myers Squibb will allow physicians access to a tissue based test that can help identify appropriate patients for treatment with repotrectinib if both the therapy and companion diagnostic are approved. This will provide more treatment options for those living with ROS1+ NSCLC and NTRK+ solid tumors.
Filed Under: Business

Show All News | Report Violation


Latest on Boston Chron